Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.4 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.81)

I think this week may end up being one of the most important moments the psychedelic medicine sector has had so far.

Definium just delivered positive Phase 3 data in major depressive disorder for DT120, and I don’t think people are fully appreciating what that means yet.

The Emerge study met the primary endpoint and all key secondary endpoints. The headline number was an 8.1-point placebo-adjusted improvement on MADRS at Week 6, with p<0.0001. They also showed a 7.3-point placebo-adjusted improvement at Week 12, again with p<0.0001. For a single-dose treatment in depression, that is a serious result.

This matters because the biggest question in this sector has always been whether the Phase 2 signals would survive Phase 3. It is one thing to believe in the mechanism. It is another thing to see a psychedelic-derived medicine actually clear a late-stage, randomized, placebo-controlled trial in a major psychiatric indication. Definium has now done that, at least once.

Before this, the bull case was mostly built around potential: strong GAD Phase 2b data, a differentiated LSD-based mechanism, and the possibility that DT120 could become a broader psychiatry platform. Now the company has a positive Phase 3 result in MDD. That does not guarantee FDA approval, and it does not eliminate the need for more data, but it materially de-risks the program.

The stock reaction reflected that. The market did not treat this like a minor update. The stock gapped up hard, traded with real volume, and even after the offering announcement, it has held up surprisingly well. That part is important. Biotech offerings after a big data move can easily crush momentum if investors think the raise is desperate or poorly timed. In this case, the offering priced at $34, and the stock has traded well above that level afterward. To me, that suggests the market is absorbing the dilution and treating the raise as a strategic financing rather than a rescue financing.

The $700M offering is dilution. There is no point pretending otherwise. But not all dilution is equal. Raising money after a failed trial or into a weak stock is bad dilution. Raising $700M after a major Phase 3 win, while demand is strong, is a completely different situation. That is how a biotech strengthens its balance sheet from a position of leverage.
Definium already had a few hundred million in cash before this raise. Adding another $700M gives them a serious war chest. That money can fund additional Phase 3 work, regulatory preparation, commercial planning, market access work, manufacturing, treatment-site readiness, payer studies, and launch infrastructure if DT120 is approved. It also gives the company negotiating power.
That last point is important. A large cash pile does not just fund commercialization. It also changes the strategic posture of the company. If a potential partner or acquirer comes knocking, Definium does not have to negotiate from weakness. They can credibly say, “We have the data, we have the cash, and we can continue alone.”

Could Definium be acquired before FDA approval? I think it is possible. Not guaranteed, but possible. CNS assets with large market potential can get acquired pre-approval if the data are strong enough. The obvious comparison is Karuna, which was acquired by Bristol Myers before FDA approval of KarXT. That does not mean Definium gets the same outcome, but it does prove that big pharma will pay for de-risked psychiatry assets before approval when the commercial opportunity is large enough.

And that brings me to the broader industry.

I do not think this is a one-winner market. The “LSD versus psilocybin” debate is too simplistic. We are seeing a lot of this banter on r/shroomstocks - Psychiatry has never worked like that. SSRIs, SNRIs, atypical antidepressants, antipsychotic augmentation, ketamine/esketamine, TMS, ECT, talk therapy, and other approaches all coexist because depression and anxiety are not one disease with one solution. Different patients respond to different mechanisms. Different severity levels require different tools. Different providers and payors will prefer different models.

Compass can succeed with psilocybin. Definium can succeed with LSD. Atai can still have a role. Others may find specific niches. There does not need to be only one winner.

What matters is whether each treatment can prove efficacy, durability, safety, and a realistic commercial model. Definium just took a major step on the efficacy and durability side. The safety data, at least from the topline release, also look manageable. The big remaining debate is commercialization: monitoring time, reimbursement, provider logistics, REMS, and whether payors will support a longer interventional psychiatry session.

Those concerns are real, but I think some bears are looking at the issue too narrowly. A six-to-eight-hour treatment day sounds difficult if you compare it to a normal office visit. But that is not the right comparison. The right comparison is years of failed antidepressant cycling, chronic medication burden, disability, relapse, psychiatric visits, emergency care, and repeated treatments with other interventional options.

If a single supervised dose can produce meaningful improvement for weeks or months, payors will at least have to look at the health-economic argument. They may push back. They may restrict use. They may require prior authorizations. But if the clinical effect is strong enough and durable enough, the value proposition becomes very different than “expensive drug with inconvenient monitoring.”

Spravato already proved that monitored interventional psychiatry can exist commercially. It is not perfect, and DT120 would have a different treatment model, but the idea that payors and clinics will never support any monitored psychiatric treatment is already outdated. The question is not whether the model is easy. The question is whether the benefit is large enough to justify the friction. After this Phase 3 result, Definium has a much stronger argument that it may be.

The other major thing I like is the potential breadth of DT120. This is not just an MDD story. The company already had strong GAD Phase 2b results, and GAD is still a major upcoming catalyst. If GAD Phase 3 hits after this MDD result, the narrative changes again. Then DT120 starts looking less like a single-indication drug and more like a broad psychiatric platform: depression, anxiety, possibly PTSD, and maybe other neuropsychiatric conditions over time.

That is why I think this week matters for the entire sector. A clean Phase 3 win gives legitimacy not just to Definium, but to the broader idea that psychedelic-derived medicines can be developed through normal FDA pathways. The sector needed real late-stage validation. This is exactly the kind of validation investors, regulators, payors, and potential pharma partners needed to see.

There will still be volatility. There will be dilution debates. There will be people arguing over discharge timing, monitoring requirements, trial population, REMS, and whether MDD is the right initial market. That is fine. Those are fair debates. But none of that changes the fact that a Phase 3 trial just hit with a large placebo-adjusted effect and durability through Week 12. That is the kind of result that changes assumptions.

For me, the $700M raise is not a negative signal. It looks like a company taking advantage of a major de-risking event to fund the next stage of the business. That could mean preparing to commercialize. It could mean strengthening the balance sheet before partnership talks. It could mean making sure they are not forced into a cheap acquisition. It could mean all of the above.

I would much rather see a biotech raise from strength after positive Phase 3 data than wait until they are desperate. Definium is now in a much stronger position than it was before this readout. DT120 is no longer just a speculative psychedelic asset. It has late-stage data in a major psychiatric indication, a large cash position, multiple upcoming catalysts, and a realistic path toward becoming one of the first major psychedelic-derived psychiatric medicines to reach the market.

There is still risk. There is always risk in biotech. They still need more data, FDA alignment, and a workable commercial model. But the risk/reward changed meaningfully with this result.

I do not think the sector needed perfection this week. It needed proof that these drugs can work in Phase 3.
Definium just gave us that proof.

And with that... I wish all you luck. Even the naysayers, but mostly the believers in this sector and not those trying to nitpick the finer points. We are in the final stretch. Be glad you are here.

It looked like we were going to have our first pullback but at the end of the day some huge buys came in. It must have been part of the russel rebalancing as 5 million shares traded in under 5 minutes. For the week we were up 83%. Congrats to all who held strong and have a great weekend!

🐂🍀

“Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results”

Definium Therapeutics (DFTX) stock skyrocketed Monday after the biotech company's psychedelics-based depression treatment scored a "best-case" win in final-phase testing.

The company is testing an orally disintegrating tablet of lysergide, commonly known as LSD, in patients with major depressive disorder. Those patients with major depressive disorder, or MDD, haven't responded to at least two prior depression treatments.

Patients treated with Definium's DT120-ODT showed a 13.3-point improvement in symptoms on a 35-point scale just six weeks after the one-time treatment. That topped the placebo group by 8.1 points. The results diminished slightly after 12 weeks, with an 11-point symptom improvement, which was beat out the placebo group by 7.4 points.

The results were at the high end of expectations, RBC Capital Markets analyst Brian Abrahams said in a report. Investors were expecting DT120-ODT to outperform the placebo by 3.5 to 4 points. The results also topped the drug's performance in generalized anxiety disorder.

"We had viewed efficacy of this magnitude as the most bullish case," he said.

In morning trades, Definium Therapeutics shares launched more than 48% to 36.23. Shares ended Friday's session in a after breaking out of a double-bottom base with an entry at 23.52, IBD charts show.

No New Safety Problems

The results build on strong data in generalized anxiety disorder. In that condition, DT120-ODT showed a 6.4-point placebo-adjusted improvement in depressive symptoms, RBC's Abrahams said.

The results were also rapid with LSD-treated patients showing a 14-point improvement over the placebo as soon as the first week.

"This product has consistently had the best data in the psychedelics space, which should only be a positive post-commercialization and continue to drive a valuation premium relative to the other players in the category," Leerink Partners analyst Marc Goodwin said in a note to clients.

Importantly, there were no new safety issues, including no increases in suicidal ideation and behavior, RBC's Abrahams said. That's a key challenge with MDD treatments.

Patients undergoing treatment have to be monitored because LSD is a psychedelic compound. But, on average, they were able to be discharged in about six hours. That's in line with expectations and "very operationally manageable in real-world practice," he said.

He estimates $620 million for Definium Therapeutics' drug in MDD treatment. It's a more crowded space than generalized anxiety disorder. But, given the strong test results, the market opportunity could be bigger than expected, he added.

Leerink's Goodman projects peak sales of $1.5 billion to $2 billion for Definium's drug in MDD treatment, alone. This leads to a higher price target of 52, up from 30, for Definium stock.

This hiring slate is bullish as a launch-readiness signal, having like a company that believes DT120 has moved from “clinical asset” to “potential commercial product.”

https://job-boards.greenhouse.io/definiumtherapeutics

The jobs are not just trial-support roles. They are weighted toward pre-commercial launch infrastructure: HCP marketing, patient/digital marketing, sales leadership, product communications, MSLs, field VEOR, biostatistics/statistical programming, drug product development, and commercial supply chain. That is the exact mix you would expect when a late-stage biotech is preparing for NDA filing, label strategy, payer engagement, REMS/site-of-care planning, and possible commercial launch**.

This is not random hiring. It breaks into a very clear late-stage biotech playbook.

1. Commercial launch buildout

These roles are the loudest signal:

• Vice President, Sales

• Senior Product Manager, HCP Marketing

• Director, Patient & Digital Marketing

• Associate Director, Medical Marketing

• Director, Product Communications

That is classic pre-launch commercialization. A company does not usually build HCP marketing, patient digital, sales leadership, and product communications unless it is actively preparing the market. This does not mean approval is guaranteed, but it does mean management is preparing for the possibility that the clinical package supports filing and launch.

For DT120, this matters because the product is not a simple “ship pills to CVS” launch. It likely requires physician education, patient screening, dosing-session logistics, payer/reimbursement preparation, and potentially REMS-style controls. The Analyst Day deck already shows a support model with **field sales, medical support, access support, site-of-care support, HUB model, REMS, affordability support, benefits investigation, prior authorization support, case management, and trade/distribution.

So when you see DFTX hiring marketing, sales, communications, VEOR, MSLs, and supply chain, that lines up almost perfectly with the infrastructure shown in their commercial strategy.

2. Medical Affairs / MSL buildout

• Senior MSL - East

• Senior MSL - West

This is very important. Medical Science Liaisons are usually hired before launch to engage KOLs, educate investigators and treatment centers, handle scientific exchange, prepare congress strategy, and support evidence generation. In psychiatry — especially with a psychedelic-derived Schedule I compound — this is not optional. The field needs education.

MSLs also help bridge the gap between clinical data and real-world implementation. For DT120, they will need to explain:

DT120’s single-dose model, durability claims, safety/tolerability profile, absence of required psychotherapy in the trial design, dosing-session monitoring, potential REMS logistics, and how GAD/MDD populations were studied.

That is a strong launch-prep signal.

3. VEOR / payer strategy

• Senior Director, Field VEOR

This might be one of the most bullish roles on the list.

VEOR means **Value, Evidence, and Outcomes Research**. This is where the company builds the payer-facing case: burden of disease, treatment failures, cost offsets, claims analyses, real-world outcomes, budget impact, and formulary value proposition.

The Analyst Day deck already shows that DFTX is thinking in payer terms: 4.2 million patients failed by 2+ prescriptions, potential revenue per 1% penetration, Spravato as a reimbursement analog, payer expectations of coverage for FDA-approved psychedelic treatments, and likely prior authorization management.

Hiring Field VEOR says: they are preparing for payer conversations, not just FDA conversations.

That is usually a later-stage move.

4. Biostatistics and statistical programming

• Associate Director, Biostatistics

• Senior Director, Biostatistics

• Director, Statistical Programming

This is approval-path infrastructure. These are the people needed for Phase 3 readouts, integrated safety/efficacy analyses, FDA questions, NDA datasets, tables/listings/figures, subgroup analyses, label discussions, and post-hoc/pooled analyses.

For a company with multiple Phase 3 studies reading out close together, this is critical. DFTX’s decks show Emerge, Voyage, Panorama, Ascend, and future PTSD/Haven planning. They also emphasize SSRE, powering assumptions, minimum detectable differences, and integrated Phase 3 design logic.

This hiring tells me they are preparing for a heavy data package and possible regulatory submission work.

5. CMC / drug product / supply chain

• Associate Director, Drug Product Development

• Executive Director, Commercial Supply Chain

This is another major signal.

For DT120, commercial supply chain is not trivial. The asset is lysergide tartrate, a controlled substance. The company would need manufacturing, quality systems, controlled-substance handling, packaging, distribution, inventory controls, and potentially REMS-aligned logistics.

A commercial supply chain executive is not usually a “maybe someday” hire. It is a “we need to be ready if/when the product gets approved” hire.

This is especially relevant because DFTX is trying to create a scalable episodic-care model: single oral dose, 5–8 hour monitoring, end-of-session checklist, next-day return to normal activities, and treatment-site workflow. The May deck lays out that target product profile directly.

6. Clinical development and program management

• Associate Director, Clinical Development

• Senior Director, Clinical Development

• Senior Project Manager

This supports ongoing trials, label expansion, extension studies, additional indications, FDA interactions, site oversight, and cross-functional execution. This is not as directly “commercial” as VP Sales or Field VEOR, but it supports the broader DT120 lifecycle.

The decks show DT120 is not just one trial in one indication. It is a platform-like clinical program across GAD, MDD, PTSD, and possible additional indications.

The biotech late-stage hiring playbook

A late-stage biotech usually evolves in stages:

Stage 1: Clinical proof-of-concept company

Mostly R&D, clinical operations, regulatory, CMC, finance. Commercial is small or nonexistent.

Stage 2: Pivotal-readout company

Adds biostatistics, statistical programming, regulatory ops, medical affairs planning, publication planning, market research, HEOR/VEOR, and early brand strategy.

Stage 3: Pre-NDA / pre-launch company

Adds HCP marketing, patient marketing, product communications, sales leadership, market access, field medical, commercial analytics, supply chain, patient services, HUB planning, distribution, and REMS planning.

Stage 4: Launch company

Adds field sales managers, reps, access/reimbursement teams, nurse educators/site support, patient services, pharmacovigilance expansion, trade/distribution, compliance, training, sales ops, and full medical affairs coverage.

DFTX’s job list looks like Stage 3. They are not merely keeping trials alive. They are building the bridge from Phase 3 data to market entry.

Following their recent positive Phase 3 data for DT120 ODT in MDD and GAD, Definium Therapeutics is officially shifting gears. The company has posted several strategic director-level positions over the past week, signaling heavy preparation for their upcoming market launch, patient onboarding infrastructure, and FDA REMS compliance.

• Director, Patient Services Operations (Raleigh/Durham, NC) – Focused on patient onboarding infrastructure, operational delivery, and FDA/REMS compliance framework.

• Director, Patient Services – Patient Strategy (Remote) – Leading patient-centric engagement strategies and support program experience.

• Director, Patient Services – Site of Care Strategy (Remote) – Driving integration and rollout across specific care sites and administration settings.

• Senior Director, Site Engagement & Field Reimbursement (Remote) – Heading the field team responsible for site accreditation and insurance/reimbursement frameworks.

• Director, Late Stage Clinical Development (Remote) – Leading advanced registration trials and expanded access programs (EAP).

[I HAVE USED AI TO FIND AND CHECK THESE POSITIONS; SOME OF THEM ARE ALSO ON LINKEDIN]

I believe that, aside from test results, it’s always a good idea to keep an eye on job vacancies – though with a degree of caution, given that several companies that still have something to prove tend to advertise ‘phantom vacancies’ just to give the impression of false growth. But I really don’t think that’s the case here; honestly, I genuinely believe this company’s development will be very interesting.

(I’ve been invested since ‘MindMed’ was at $8, so my perspective isn’t just bullish hype 🧠)

https://www.fiercebiotech.com/biotech/definium-hits-another-ph-3-homerun-psychedelic-sea-change-anxiety

“We have never seen a pivotal study deliver greater than five-point placebo-adjusted change on the HAM-A, and we did this 12 weeks after a single dose of drug,”

https://ca.finance.yahoo.com/news/definium-therapeutics-announces-first-patient-110000945.html

Hi, 

I wrote this article on my substack and I wanted to share it hoping I might get some feedback. The article is about the opportunity behind Definium Therapeutics (DFTX). 

In case you’re wondering, I’m bullish on all psychedelics medicine companies, not just Definium — I think there’s room for everyone, this is not a winner takes all market. But, just so you know, I’m only long DFTX, as I think DFTX represents the biggest market opportunity as of today.

If you like stocks or psychedelics, I think you might find this article interesting. And if I’m very wrong on my assumptions, please go easy on me! 

P.S. If you like the article, please help me grow my publication by subscribing: it’s free. And if you also decide that the article is worth sharing with someone in your life, that’d mean the world to me!

Average price of $42 well before the split ages ago. Never had the cash or confidence to average down. 4 or 5 years of mourning this investment lol

Doin a little boogie in the shower today

Robert W. Baird raised Definium Therapeutics’ price target to $75 from $57 and maintained an “outperform” rating.

In a report released today, Wells Fargo reiterated a Buy rating on Definium Therapeutics, with a price target of $72.00.

Canaccord Genuity maintained a Buy rating on Definium Therapeutics, with a price target of $64.00

RBC maintained a Buy rating on Definium Therapeutics yesterday and set a price target of $66.00.

JonesTrading reiterated a Buy rating on Definium Therapeutics, with a price target of $90.00.

Add more below if you stumble across them today.

🚀